BioCryst Pharmaceuticals is trading 5.31% lower at $8.12 after Q3 earnings and revenue beats; licensing revenue and international RAPIVAB orders drove the higher total revenue outlook, which may have tempered the positive headlines.
- The quarter included an upper-teens-million-dollar one-time inventory build.
- Full-year ORLADEYO revenue guidance was maintained at $625 million–$645 million.
- Broader markets and biotech were higher and do not appear to explain the decline; current volume information was unavailable.